선암 이외의 진행성 폐암에 대한항암화학요법 및 표적 치료 - 신경내분비암

키워드

참고문헌 (83)

1. Travis W, "WHO classification of tumors of the lung, pleura, thymus and heart" (2015), IARC Press
2. Travis W, "Pathology and genetics of tumors of the lung, pleura, thymus and heart" (2004), IARC Press
3. Gustafsson BI, "Bronchopulmonary neuroendocrine tumors", Cancer, 113, pp.5~21 (2008)
4. Travis WD, "Advances in neuroendocrine lung tumors", Ann Oncol, 21(Suppl 7), pp.65~71 (2010)
5. Naalsund A, "Carcinoid lung tumors-incidence, treatment and outcomes : a population-based study", Eur J Cardiothorac Surg, 39, pp.565~569 (2011)
6. Soga J, "Bronchopulmonary carcinoids : an analysis of 1, 875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties", Ann Thorac Cardiovasc Surg, 5, pp.211~219 (1999)
7. Derks JL, "Clinical features of large cell neuroendocrine carcinoma : a population-based overview", Eur Respir J (2015)
8. Patel MI, "US lung cancer trends by histologic type", Cancer, 121, pp.1150~1152 (2015)
9. Hassan MM, "Risk factors associated with neuroendocrine tumors : a U.S.-based case-control study", Int J Cancer, 123, pp.867~873 (2008)
10. Beasley MB, "Pulmonary atypical carcinoid : predictors of survival in 106 cases", Hum Pathol, 31, pp.1255~1265 (2000)
11. Froudarakis M, "Bronchial carcinoids. A review of 22 cases", Oncology, 53, pp.153~158 (1996)
12. Fink G, "Pulmonary carcinoid : presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature", Chest, 119, pp.1647~1651 (2001)
13. Faggiano A, "Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study : the NET management study", J Endocrinol Invest, 35, pp.817~823 (2012)
14. García-Yuste M, "Typical and atypical carcinoid tumours : analysis of the experience of the Spanish multi-centric study of neuroendocrine tumours of the lung", Eur J Cardiothorac Surg, 31, pp.192~197 (2007)
15. Travis WD, "Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid", Am J Surg Pathol, 22, pp.934~944 (1998)
16. Lim E, "The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors", J Thorac Cardiovasc Surg, 130, pp.969~972 (2005)
17. Glazer ES, "Long-term survival after surgical management of neuroendocrine hepatic metastases", HPB(Oxford), 12, pp.427~433 (2010)
18. Nussbaum DP, "Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors", Ann Thorac Surg, 99, pp.428~434 (2015)
19. Mackley HB, "Primary carcinoid tumors of the lung : a role for radiotherapy", Oncology(Williston Park), 20, pp.1537~1543 (2006)
20. Thomas CF Jr, "Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement", Chest, 119, pp.1143~1150 (2001)
21. "NCCN clinical practice guidelines in oncology (NCCN Guideliens®) : Small cell lung cancer" (2015)[URL]
22. Caplin ME, "Pulmonary neuroendocrine(carcinoid)tumors : European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids", Ann Oncol, 26, pp.1604~1620 (2015)
23. Veronesi G, "Large cell neuroendocrine carcinoma of the lung : a retrospective analysis of 144 surgical cases", Lung Cancer, 53, pp.111~115 (2006)
24. Grand B, "High grade neuroendocrine lung tumors : pathological characteristics, surgical management and prognostic implications", Lung Cancer, 81, pp.404~409 (2013)
25. Iyoda A, "Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features", Cancer, 92, pp.1108~1112 (2001)
26. Saji H, "Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy", Anticancer Drugs, 21, pp.89~93 (2010)
27. Iyoda A, "Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma", J Thorac Cardiovasc Surg, 138, pp.446~453 (2009)
28. Sarkaria IS, "Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas : a single institution experience", Ann Thorac Surg, 92, pp.1180~1186 (2011)
29. Iyoda A, "Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma", Ann Thorac Surg, 82, pp.1802~1807 (2006)
30. Kenmotsu H, "A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma(large cell neuroendocrine carcinoma and small cell lung cancer)", Lung Cancer, 84, pp.254~258 (2014)
31. Eba J, "A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma(JCOG1205", 1206), 2014, pp.44, 379~382
32. McCaughan BC, "Bronchial carcinoids. Review of 124 cases", J Thorac Cardiovasc Surg, 89, pp.8~17 (1985)
33. Rekhtman N, "Neuroendocrine tumors of the lung : an update", Arch Pathol Lab Med, 134, pp.1628~1638 (2010)
34. Hörsch D, "Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors) : current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany", Oncol Res Treat, 37, pp.266~276 (2014)
35. Rubin J, "Octreotide acetate longacting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome", J Clin Oncol, 17, pp.600~606 (1999)
36. Ruszniewski P, "Rapid and sustained relief from the symptoms of carcinoid syndrome : results from an open 6-month study of the 28-day prolongedrelease formulation of lanreotide", Neuroendocrinology, 80, pp.244~251 (2004)
37. O'Toole D, "Treatment of carcinoid syndrome : a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance", Cancer, 88, pp.770~776 (2000)
38. Vinik A, "ELECT Study Group. ELECT : A phase 3 study of efficacy and safety of lanreotide autogel", depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs), 2014, pp.32(suppl 3), 268~
39. Kvols LK, "Pasireotide(SOM230)shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study", Endocr Relat Cancer, 19, pp.657~666 (2012)
40. Wolin EM, "Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues", Drug Des Devel Ther, 9, pp.5075~5086 (2015)
41. Rinke A, "Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID study group", J Clin Oncol, 27, pp.4656~4663 (2009)
42. Martín-Richard M, "Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours : a Spanish, multicentre, open-label, single arm phase II study", BMC Cancer, 13, pp.427~ (2013)
43. Caplin ME, "Lanreotide in metastatic enteropancreatic neuroendocrine tumors", N Engl J Med, 371, pp.224~233 (2014)
44. Cives M, "Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors", Endocr Relat Cancer, 22, pp.1~9 (2015)
45. Öberg K, "ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 23(Suppl 7), pp.120~123 (2012)
46. Moreno A, "Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors", Endocr Relat Cancer, 15, pp.257~266 (2008)
47. Yao JC, "Everolimus for advanced pancreatic neuroendocrine tumors", N Engl J Med, 364, pp.514~523 (2011)
48. Lombard-Bohas C, "Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors : a subgroup analysis of the phase III RADIANT-3 trial", Pancreas, 44, pp.181~189 (2015)
49. "Everolimus plus best supportive care vs placebo plus best supportive care in the treatment of patients with advanced neuroendocrine tumors (GI or Lung Origin) (RADIANT-4)" (2015)[URL]
50. Pavel ME, "Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome(RADIANT-2) : a randomised, placebo-controlled, phase 3 study", Lancet, 378, pp.2005~2012 (2011)
51. Fazio N, "Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors : analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study", Chest, 143, pp.955~962 (2013)
52. Bajetta E, "Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors : an ITMO group study", Cancer, 120, pp.2457~2463 (2014)
53. Chan JA, "Phase I study of pasireotide(SOM 230)and everolimus(RAD001)in advanced neuroendocrine tumors", Endocr Relat Cancer, 19, pp.615~623 (2012)
54. "3-arm trial to evaluate pasireotide LAR/everolimus alone/in combination in patients with lung/thymus NET - LUNA trial" (2015)[URL]
55. Kulke MH, "Activity of sunitinib in patients with advanced neuroendocrine tumors", J Clin Oncol, 26, pp.3403~3410 (2008)
56. Blumenthal GM, "FDA approval summary : sunitinib for the treatment of progressive welldifferentiated locally advanced or metastatic pancreatic neuroendocrine tumors", Oncologist, 17, pp.1108~1113 (2012)
57. Yao JC, "Targeting vascular endothelial growth factor in advanced carcinoid tumor : a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b", J Clin Oncol, 26, pp.1316~1323 (2008)
58. Hobday TJ, "Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors", J Clin Oncol, 33, pp.1551~1556 (2015)
59. Mitry E, "Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal(GINETs)tract(BETTER trial)--a phase II non-randomised trial", Eur J Cancer, 50, pp.3107~3115 (2014)
60. Berruti A, "Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors : the XELBEVOCT study", BMC Cancer, 14, pp.184~ (2014)
61. Ducreux M, "Bevacizumab combined with 5-FU", streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours(BETTER trial)--a phase II non-randomised trial, 2014, pp.50, 3098~3106
62. Castellano D, "Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour : a phase II study of Spanish neuroendocrine tumour group(GETNE0801)", Eur J Cancer, 49, pp.3780~3787 (2013)
63. Chan JA, "Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors", J Clin Oncol, 30, pp.2963~2968 (2012)
64. Koumarianou A, "Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours", Endocr Relat Cancer, 19, pp.1~4 (2012)
65. Moertel CG, "Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome", Cancer Clin Trials, 2, pp.327~334 (1979)
66. Engstrom PF, "Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor", J Clin Oncol, 2, pp.1255~1259 (1984)
67. Dahan L, "Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors : FNCLCC-FFCD 9710", Endocr Relat Cancer, 16, pp.1351~1361 (2009)
68. Sun W, "Phase II", III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors : Eastern Cooperative Oncology Group Study E1281, 2005, pp.23, 4897~4904
69. Crona J, "Effect of temozolomide in patients with metastatic bronchial carcinoids", Neuroendocrinology, 98, pp.151~155 (2013)
70. Ekeblad S, "Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors", Clin Cancer Res, 13, pp.2986~2991 (2007)
71. Fine RL, "Capecitabine and temozolomide(CAPTEM)for metastatic, well-differentiated neuroendocrine cancers : the Pancreas Center at Columbia University experience", Cancer Chemother Pharmacol, 71, pp.663~670 (2013)
72. Abbasi S, "Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors : Jordan experience", Pancreas, 43, pp.1303~1305 (2014)
73. Kulke MH, "Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors", J Clin Oncol, 24, pp.401~406 (2006)
74. Rieber J, "Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas", Eur J Med Res, 20, pp.64~ (2015)
75. Le Treut J, "Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma : the GFPC 0302 study", Ann Oncol, 24, pp.1548~1552 (2013)
76. Sun JM, "Chemotherapy for pulmonary large cell neuroendocrine carcinoma : similar to that for small cell lung cancer or non-small cell lung cancer?", Lung Cancer, 77, pp.365~370 (2012)
77. Kozuki T, "Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma", J Cancer Res Clin Oncol, 131, pp.147~151 (2005)
78. Glisson BS, "Large-cell neuroendocrine carcinoma : controversies in diagnosis and treatment", J Natl Compr Canc Netw, 9, pp.1122~1129 (2011)
79. Otte A, "Yttrium-90 DOTATOC : first clinical results", Eur J Nucl Med, 26, pp.1439~1447 (1999)
80. van Essen M, "Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin", Eur J Nucl Med Mol Imaging, 34, pp.1219~1227 (2007)
81. -D-Phe1-Tyr3-octreotide(90Y-DOTATOC)in the treatment of neuroendocrine tumours : a clinical phase II study, "Ann Oncol", 2001, 941~945
82. -TOC in metastasized neuroendocrine cancers, "J Clin Oncol", 2011, 2416~2423
83. octreotate : toxicity, efficacy, and survival, "J Clin Oncol", 2008, 2124~2130

관련 논문AI추천